การผลิตสารเภสัชรังสีและที่มาของศูนย์เพทซีทีและไซโคลตรอน มหาวิทยาลัยเชียงใหม่
Article Sidebar
Main Article Content
บทคัดย่อ
เพทซีที (positron emission tomography - computed tomography หรือ PET/CT) เป็นเทคโนโลยีการตรวจที่เป็นมาตรฐาน ในการวินิจฉัยโรคมะเร็งชนิดต่าง ๆ โดยการถ่ายภาพการกระจายตัวของสารเภสัชรังสีซึ่งจะแสดงถึงขบวนการทางชีววิทยาต่าง ๆ ในร่างกายมนุษย์ โดยการใช้สารเภสัชรังสีที่ผลิตจากเครื่องไซโคลตรอน แม้ว่าในประเทศไทยจะมีเครื่องไซโคลตรอนที่กรุงเทพมหานครฯตั้งแต่ปี พ.ศ. 2548 แต่ยังไม่มีการใช้อย่างแพร่หลายโดยทั่วไป ศูนย์เพทซีทีและไซโคลตรอน มหาวิทยาลัยเชียงใหม่ เปิดบริการในปี พ.ศ. 2556 เป็นศูนย์ไซโคลตรอนศูนย์แรกในส่วนภูมิภาค ที่มีเครื่อง
ไซโคลตรอนที่มีประสิทธิภาพสูง สามารถผลิตสารเภสัชรังสีชนิดต่าง ๆ สำหรับการตรวจเพทซีที เช่น ฟลูออรีน-18, คาร์บอน- 11, ไนโตรเจน-13, ออกซิเจน-15, และ ไอโอดีน-124 ในบทความนี้จะกล่าวถึงที่มาและภาพรวมของขบวนการผลิตสารเภสัชรังสีทั้งหมด ที่ใช้ในทาง การแพทย์และการวิจัย ทั้งในโรคมะเร็ง โรคหัวใจ และโรคทางสมอง เชียงใหม่เวชสาร 2564;60(1):125-34. doi 10.12982/CMUMEDJ.2021.11
Article Details
อนุญาตภายใต้เงื่อนไข Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เอกสารอ้างอิง
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2015 (GBD 2015) Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years 1990-2015 [Internet]. Insti-tute for Health Metrics and Evaluation (IHME). 2016 [cited 2020 March 24]. Available from: http://ghdx.healthdata.org/record/ihme-data/gbd-2015-cancer-incidence-mortality-ylls-ylds-dalys-1990-2015
Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET/CT imaging in oncology. Ann Saudi Med. 2011; 31:3-13.
Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, et al. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomogra-phy alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg [Internet]. 2007;70:331-8. [cited 2019 March 26]. Available from: http://europepmc.org/abstract/MED/18330088
Long G. The biopharmaceutical pipeline: innovative therapies in clinical development. Anal Group Econ Financ Strateg Consult [Internet]. 2017;36. [cited 2019 June 08]. Available from: https://www.phrma.org/report/the-biopharmaceutical-pipeline%0Ahttps://ge.ent.box.com/file/480478182638
Waaijer SJH, Kok IC, Eisses B, Schröder CP, Jalving M, Brouwers AH, et al. Molecular imaging in cancer drug develop-ment. J Nucl Med. 2018;59:726–32.
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.
Salem SS, Shahin MA. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun. 2012;33:313–21.
Sager O, Dinçoğlan F, Demiral S, Uysal B, Gamsız H, Elcim Y, et al. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective. Curr Radiopharm. 2019;12:4–10.
Schöder H, Gönen M. Screening for cancer with PET and PET/CT: Potential and limitations. J Nucl Med. 2007;48(1 Suppl.):4–19.
Chanachai R. Report of FNCA workshop on Cyclotron and PET in Medicine Project 2010 [Internet]. 2011 [cited 2020 March 20]. Available from: www.fnca.mext.go.jp/english/pet/e_ws_2010.html
Ruangma A. FDG-PET and FDG production at Wattanosoth Hospital. Bangkok Med J. 2013;05(01):80–9.
United Nations Data: Thailand-Country profile [Internet]. 2019. [cited 2020 March 25]. Available from: http://data.un.org/en/iso/th.html
Hricak H, Choi BI, Scott AM, Sugimura K, Muellner A, Von Schulthess GK, et al. Global trends in hybrid imaging. Ra-diology. 2010;257:498–506.
Yamabhai I, Praditsitthikorn N, Chotipanich C, Chiewvit S, Srwasubat A, Ratchadara S, et al. Appropriateness of Using Positron Emission Tomography Computed Tomography (PET/CT) in Thailand. J Heal Sci. 2001;20:222–34.
Locharernkul C. Challenges in setting up a PET programme: Thailand experience. Int Conf Clin PET Mol Nucl Med (IPET 2007) [Internet]. 2007. p. 26–7. [cited 2019 July 15]. Available from: https://inis.iaea.org/collection/NCLCollectionStore/_Public/39/008/39008755.pdf
Dondi M, Kashyap R, Paez D, Pascual T, Zaknun J, Bastos FM, et al. Trends in nuclear medicine in developing countries. J Nucl Med. 2011;52(Suppl 2):16–24.
International Atomic Energy Agency. Regional Cooperative Agreement: 2014 Annual Report. 2014.
Watanabe Y. Molecular Imaging-based Early-Phase and Exploratory Clinical Research. 2013;133:187–95.
International Atomic Energy Agency. Competency based hospital radiopharmacy training. Training Course Series No. 39, Vienna: IAEA; 2010. p. 2.
National Research Council. Assuring a future U.S.-based nuclear and radiochemistry expertise. Washington, DC: The Na-tional Academies Press; 2012. p. 60.
Scott PJH, Hockley BG. Radiochemical Syntheses. Radiopharmaceuticals for Positron Emission Tomography. New Jersey: Wiley, John Wiley & Sons; 2012.
Giesel FL, Cardinale J, Schäfer M, Neels O, Benešová M, Mier W, et al. 18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43:1929–30.
Iida H, Kanno I, Takahashi A, Miura S, Murakami M, Takahashi K, et al. Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation. 1988;78:104–15.
Braghirolli AMS, Waissmann W, da Silva JB, dos Santos GR. Production of iodine-124 and its applications in nuclear medicine. Appl Radiat Isot. 2014;90:138-48.
Strijckmans K. The isochronous cyclotron: principles and recent developments. Comput Med Imaging Graph. 2001;25:69-78.
Stöcklin G, Pike VW. Radiopharmaceuticals for positron emission tomography - methodological aspects. Netherlands: Springer; 1993. p. 1–43.
Coenen, H. H., Mertens, John, Mazière B. Radioionidation Reactions for Pharmaceuticals Compendium for Effective Synthesis Strategies. Springer Science+Business Media B.V. Springer, Dordrecht: Netherlands; 2006. p. 11–1.
K. Hamacher, H.H. Coenen GS. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-Fluoro-2-Deoxy-D-Glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–8.
Naka S, Watabe T, Soeda F, Kanai Y, Neels O, Kopka K, et al. Synthesis of 18F-PSMA-1007 injection using single use cassette for GMP. J Nucl Med. 2018;59(supplement 1 1036).
Cardinale J, Martin R, Remde Y, Schäfer M, Hienzsch A, Hübner S, et al. Procedures for the GMP-compliant production and quality control of [18F]PSMA-1007: A next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals. 2017;10:1-18.
Blau M, Nagler W, Bender MA. Fluorine-18: A new isotope for bone scanning. 1962;3332-4.
Wieland B, Bida GT, Padgett HC, Hendry G, Zippi EM, Kabalka GW, et al. In-target production of [13N]ammonia via proton irradiation of dilute aqueous ethanol and acetic acid mixtures. Int J Rad Appl Instrum A. 1991; 42:1095–8.
Ishiwata K, Vaalburg W, Elsinga PH, Paans AMJ, Woldring MG. Comparison of L-[1-11C] methionine and L-methyl-[11C]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med. 1988;29:1419-27.
Kuznetsova OF, Fedorova OS, Vasil’ev DA, Simonova TP, Nader M, Krasikova RN. Preparation and quality control of [N-methyl-11C]choline for routine PET application. Radiochemistry. 2003;45:377–81.
Le Bars D, Malleval M, Bonnefoi F, Tourvieille C. Simple synthesis of [1-11C]acetate. J Label Compd Radiopharm. 2006;49:263–7.
Ruiz HV, Wolf AP. Direct synthesis of oxygen-15 labelled water at high specific activities. J Label Compd Radiopharm. 1978;15:185-9.
Qaim SM, Hohn A, Bastian T, El-Azoney KM, Blessing G, Spellerberg S, et al. Some optimisation studies relevant to the production of high-purity 124I and 120gI at a small-sized cyclotron. Appl Radiat Isot. 2003;58:69–78.
Nagatsu K, Fukada M, Minegwashi K, Suzuki H, Fukumura T, Yamazaki H, Suzuki K. Fully automated production of iodine-124 using a vertical beam. Appl Radiat Isot. 2011;69:146-57.
Forum for Nuclear Cooperation in Asia (FNCA) Cyclotron and Positron Emission Tomography (PET) in medicine. Guideline for quality assurance and quality control of 18F-FDG(2-Deoxy-2-fluoro-D-glucose). 2011; [cited 2019 Decem-ber 09]. Available from: www.fnca.mext.go.jp/english/pet/guideline_2.pdf
Council of Europe. European Pharmacopoeia (Ph. Eur.). 10th ed. France: Strasbourg; 2020. p. 1190.
Pharmaceutical Inspection Convention Pharmaceutical Inspection Co-operation Scheme. PIC/S Guide to good practices for the preparation of medicinal products in healthcare establishments. PE 010-4. 2014;3:1–56. [cited 2019 December 17]. Available from: http://www.picscheme.org/publication.php.
International Atomic Energy Agency. Strengthening Radiation Medicine Capacities at Chiang Mai University, Thailand [Internet]. 2014 [cited 2020 Mar 26]. Available from: https://www.iaea.org/newscenter/news/strengthening-radiation-medicine-capacities-at-chiang-mai-university-thailand
